4//SEC Filing
O'Neill Gilmore Neil 4
Accession 0001650664-25-000089
CIK 0001650664other
Filed
Jun 3, 8:00 PM ET
Accepted
Jun 4, 6:36 PM ET
Size
14.1 KB
Accession
0001650664-25-000089
Insider Transaction Report
Form 4
O'Neill Gilmore Neil
DirectorCEO
Transactions
- Sale
Common Stock
2025-06-03$1.72/sh−15,192$26,196→ 280,282 total
Footnotes (2)
- [F1]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2025. The sale does not represent a discretionary trade by the Reporting Person.
- [F2]This transaction was executed in multiple trades at prices ranging from $1.7239 to $1.7566 . The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Issuer
Editas Medicine, Inc.
CIK 0001650664
Entity typeother
Related Parties
1- filerCIK 0001742084
Filing Metadata
- Form type
- 4
- Filed
- Jun 3, 8:00 PM ET
- Accepted
- Jun 4, 6:36 PM ET
- Size
- 14.1 KB